Evidence map›Paper›PMID 38637659›Full record

ArticleScientific reports2024

Analysis of plasma metabolomes from 11 309 subjects in five population-based cohorts.

Nilanjana Ghosh, Carl Lejonberg, Tomasz Czuba, Koen Dekkers, Richard Robinson, Johan Ärnlöv, Olle Melander, Maya Landenhed Smith, Anne M Evans, Olof Gidlöf and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  3. Article
  4. Article
  5. Observational
  6. Frontiers in microbiology · 2026
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nilanjana GhoshThe Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and the Department of Cardiology, Sahlgrenska University Hospital, SE-413 45, Gothenburg, Sweden.
Carl LejonbergDepartment of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.
Tomasz CzubaThe Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and the Department of Cardiology, Sahlgrenska University Hospital, SE-413 45, Gothenburg, Sweden.
Koen DekkersMolecular Epidemiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Richard RobinsonMetabolon Inc, Morrisville, NC, 27560, USA.
Johan ÄrnlövDivision of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
Olle MelanderDepartment of Internal Medicine, Clinical Sciences, Lund University, Malmö, Sweden.
Maya Landenhed SmithDepartment of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and the Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
Anne M EvansMetabolon Inc, Morrisville, NC, 27560, USA.
Olof GidlöfDepartment of Cardiology, Clinical Sciences, Lund University, Lund, Sweden.
Robert E GersztenDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Lars LindDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Gunnar EngströmCardiovascular Epidemiology, Clinical Sciences, Lund University, Malmö, Sweden.
Tove FallMolecular Epidemiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
J Gustav SmithThe Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and the Department of Cardiology, Sahlgrenska University Hospital, SE-413 45, Gothenburg, Sweden. gustav.smith@wlab.gu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma metabolomics holds potential for precision medicine, but limited information is available to compare the performance of such methods across multiple cohorts. We compared plasma metabolite profiles after an overnight fast in 11,309 participants of five population-based Swedish cohorts (50-80 years, 52% women). Metabolite profiles were uniformly generated at a core laboratory (Metabolon Inc.) with untargeted liquid chromatography mass spectrometry and a comprehensive reference library. Analysis of a second sample obtained one year later was conducted in a subset. Of 1629 detected metabolites, 1074 (66%) were detected in all cohorts while only 10% were unique to one cohort, most of which were xenobiotics or uncharacterized. The major classes were lipids (28%), xenobiotics (22%), amino acids (14%), and uncharacterized (19%). The most abundant plasma metabolome components were the major dietary fatty acids and amino acids, glucose, lactate and creatinine. Most metabolites displayed a log-normal distribution. Temporal variability was generally similar to clinical chemistry analytes but more pronounced for xenobiotics. Extensive metabolite-metabolite correlations were observed but mainly restricted to within each class. Metabolites were broadly associated with clinical factors, particularly body mass index, sex and renal function. Collectively, our findings inform the conduct and interpretation of metabolite association and precision medicine studies.

Indexed as

MetabolomeMetabolomicsAmino AcidsFemaleHumansMalePlasmaSwedenAmino Acids

Identifiers

PMID38637659
PMCPMC11026396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.